NESP

This brand name is authorized in Hong Kong, Japan, Singapore

Active ingredients

The drug NESP contains one active pharmaceutical ingredient (API):

1 Darbepoetin alfa
UNII 15UQ94PT4P - DARBEPOETIN ALFA

Darbepoetin alfa stimulates erythropoiesis by the same mechanism as the endogenous hormone. Darbepoetin alfa has five N-linked carbohydrate chains whereas the endogenous hormone and recombinant human erythropoietins (r-HuEPO) have three. The additional sugar residues are molecularly indistinct from those on the endogenous hormone. Due to its increased carbohydrate content darbepoetin alfa has a longer terminal half-life than r-HuEPO and consequently a greater in vivo activity.

Read about Darbepoetin alfa

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
B03XA02 Darbepoetin alfa B Blood and blood forming organs → B03 Antianemic preparations → B03X Other antianemic preparations → B03XA Other antianemic preparations
Discover more medicines within B03XA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: HK Department of Health Drug Office Identifier(s): 63111, 63112, 63115, 63117
Country: JP 医薬品医療機器総合機構 Identifier(s): 3999425S5028, 3999425S6024, 3999425S7020, 3999425S8027, 3999425S9023, 3999425U1023, 3999425U2020, 3999425U3026, 3999425U4022
Country: SG Health Sciences Authority Identifier(s): 14739P, 14740P, 14741P, 14742P, 14743P, 14744P, 14745P

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.